What Redmile Group does

Redmile Group is a San Francisco-based healthcare investment firm founded in 2007 that deploys venture, growth, and crossover capital into biotechnology and life sciences companies. According to firmographics, it operates with 11-50 employees and reported $1.358 billion in reportable AUM as of a February 2026 SEC filing tied to its Nurix Therapeutics position. The firm invests across therapeutic areas including oncology, metabolic disease, genetic hearing loss, and inflammatory conditions, and across the full capital stack from Series B venture rounds to PIPEs, registered offerings, reserved capital increases, and direct open-market equity purchases.

The portfolio reflects a concentration in clinical-stage and commercially-staged biopharmaceutical platforms, with disclosed positions including Absci (AI-designed antibodies), Obsidian Therapeutics (tumor infiltrating lymphocyte cell therapy via reverse merger), Ambrosia Biosciences (oral small molecule GLP-1), Nurix Therapeutics (BTK degrader, 11.31% stake), Scholar Rock (latent myostatin inhibitor, 16.94% stake), Sensorion (gene therapy for hearing loss), ADC Therapeutics (ZYNLONTA), Bambusa Therapeutics (bispecific antibodies), and Augmedix (AI medical documentation). Redmile frequently participates alongside strategic pharma and tier-1 specialist investors such as Eli Lilly, Sanofi, TCGX, RA Capital, Blue Owl Healthcare Opportunities, and Deep Track Capital, and has co-led rounds including Ambrosia's $100 million Series B.

The firm's revenue model is conventional for a healthcare-focused private investment manager: management fees on AUM plus carried interest on portfolio realizations. There is no product, software, or technology platform of its own; pricing, distribution channels, and customer segmentation in the traditional sense do not apply. Limited partner composition, fund vintage, leadership compensation, and detailed ownership of the management company are not disclosed in available source material, and the firm has no public listing or parent company identified.

Name

Redmile Group

Website

https://redmilegroup.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Redmile Group is a San Francisco-based, healthcare-focused private investment firm founded in 2007 that deploys venture, growth, and crossover capital into clinical-stage and commercial biotechnology companies across multiple therapeutic areas.

Ownership category

akta.pro rank

Product category

Healthcare Investment Management

NAICS

Portfolio Management and Investment Advice (523940)

akta.pro primary industry

Private Sector & Blended Finance Arms (IFC-type) (BPADACAJ)

Keywords

• Healthcare venture capital
• Biotech investment management
• Life sciences investing
• Crossover fund management
• Biotechnology equity investments

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Others

Revenue model

1. Investment Returns and Fund Management: Redmile Group generates returns through equity investments in biotech and life sciences companies, participating in financing rounds such as Series B, PIPE offerings, registered offerings, and direct stock purchases. The firm holds significant stakes in portfolio companies (e.g., 11.31% of Nurix Therapeutics, 16.94% of Scholar Rock), and its $1.358 billion in reportable AUM suggests a fund management model where returns are realized through capital appreciation and exit events in its portfolio companies.

Core offering

Redmile Group is a healthcare-focused investment firm that deploys venture, growth, and crossover capital into biotechnology and life sciences companies. The firm invests across multiple stages and instruments — including private financings (e.g., Series B) and public-market securities — targeting therapeutic developers, platform biotech, and healthcare technology businesses.

Product overview

Redmile Group is a venture capital and investment management firm specializing in the biotechnology and life sciences sector. The company invests in clinical-stage biopharmaceutical companies developing therapeutic programs across various disease areas including oncology, metabolic disorders, genetic hearing loss, and inflammatory conditions. As an investment firm, Redmile Group does not offer commercial products or technology platforms; its offering consists of capital investment and strategic support to portfolio companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare venture and growth equity investments
• Public-equity and PIPE investments in healthcare

Quantifiable outcome

• Portfolio company Absci raised $100 million in a stock offering with Redmile participation, with shares rising 22% post-announcement.
• +4 more outcomes

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• RA Capital Management: Healthcare-focused crossover and venture investor that participates across private and public biotech financings. Directly comparable to Redmile in mandate, including co-investments in companies like Bambusa Therapeutics.
• Baker Bros. Advisors: Long-only healthcare and life sciences investment firm with deep biotech exposure across private rounds and public equities. Comparable to Redmile as a specialist healthcare investor building concentrated public/private positions.
• Orbimed Advisors: Healthcare-dedicated investment platform spanning venture, growth, and public equities with multi-billion AUM. Directly comparable to Redmile in cross-stage healthcare deployment.
• Perceptive Advisors: Healthcare-focused investment manager deploying capital across biotech equities and private financings. Similar crossover mandate and therapeutic breadth as Redmile.
• Cormorant Asset Management: Healthcare-focused hedge fund with public/private biotech crossover strategy. Directly comparable to Redmile in mandate and concentrated small/mid-cap biotech positioning.
• EcoR1 Capital: Biotech-focused investment firm specializing in private and public healthcare equities. Highly comparable to Redmile in size, focus, and crossover deployment style.
• Atlas Venture: Early-stage life sciences venture firm building biotech companies from inception through clinical development. Comparable to Redmile's biotech focus, though more weighted to earlier stages.
• ARCH Venture Partners: Leading healthcare and biotech venture firm investing across company formation through later stages. Comparable as a dedicated life sciences investor, though generally earlier-stage orientation.
• Venrock Healthcare Partners: Healthcare-focused investment franchise associated with Venrock, deploying across public and private biotech. Comparable to Redmile's crossover healthcare strategy.

Broad incumbents

• Deerfield Management: Large, established healthcare investment firm with multi-strategy mandates spanning venture, public equities, royalties, and credit. Overlaps with Redmile in biotech equity investing but operates a broader platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/redmile-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments216 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Redmile Group